Denali Therapeutics INC Form 4 insider transactions

Ryan J. Watts, President and CEO and a Director of Denali Therapeutics Inc., reported a transaction in 32,220 shares of common stock on August 12, 2026.

Alexander O. Schuth, COFO and Secretary of Denali Therapeutics Inc., sold 2,857 shares of common stock on August 11, 2026 for $25.07 per share.

Director Jay Flatley was granted 6,408 restricted stock units and 19,226 stock options as part of annual compensation for his role on the board.

Director Peter S. Klein was awarded 6,408 restricted stock units and 19,226 stock options as part of his compensation package at Denali Therapeutics.

Director Steve E. Krognes was granted 6,408 restricted stock units and 19,226 stock options as part of annual board compensation.

Director David P. Schenkein was granted 6,408 restricted stock units and 19,226 stock options as part of annual compensation for his role on the board.

Director Nancy Thornberry was granted 6,408 restricted stock units and 19,226 stock options as part of her annual compensation package.

Director Timothy Van Hauwermeiren received an equity grant of 6,408 RSUs and 19,226 stock options from Denali Therapeutics.

Denali Therapeutics director Jennifer E. Cook was granted 6,408 restricted stock units and 19,226 stock options.

Director Julian C. Baker received a grant of restricted stock units and stock options from Denali Therapeutics Inc. as part of his board compensation.

Denali Therapeutics Inc. CEO Ryan J. Watts sold 35,198 shares of common stock at $16.5 per share to cover tax obligations related to vested restricted stock units.

Denali Therapeutics' Chief Financial Officer and Secretary, Alexander O. Schuth, sold 17,218 shares of common stock to cover tax liabilities from vested restricted stock units.

Denali Therapeutics' COFO and Secretary, Alexander O. Schuth, was granted 57,700 Restricted Stock Units and options to purchase 173,100 shares of common stock.

Denali Therapeutics Inc. CEO Ryan J. Watts received grants of 78,960 Restricted Stock Units and options to purchase 236,880 shares of common stock.

Baker Bros. Advisors' affiliated funds acquired over 2.2 million prefunded warrants in Denali Therapeutics through a public offering.

Denali Therapeutics Inc. Director Timothy Van Hauwermeiren reported the acquisition of common stock and stock options.

Denali Therapeutics CEO Ryan Watts reported a charitable contribution of 50,000 shares of common stock.

Denali Therapeutics' COFO and Secretary, Alexander O. Schuth, sold 2,937 shares of common stock to cover tax obligations related to vested restricted stock units.

Denali Therapeutics' Chief Medical Officer, Carole Ho, sold shares to cover tax obligations and under a pre-arranged trading plan.

Denali Therapeutics' Chief Medical Officer, Carole Ho, exercised 44,655 stock options at $0.68 per share, increasing her direct common stock holdings.

Denali Therapeutics Inc.'s President and CEO, Ryan J. Watts, reported the exercise of stock options and subsequent sale of common stock totaling 495,282 shares, primarily under a Rule 10b5-1 trading plan.

Denali Therapeutics Inc. disclosed that director Julian C. Baker was granted 10,565 restricted stock units and 31,695 non-qualified stock options as compensation, with the pecuniary interest indirectly benefiting Baker Bros. affiliated funds.

Denali Therapeutics Inc. Director Jennifer E. Cook reported the acquisition of 6,037 Restricted Stock Units and 18,111 stock options on June 3, 2025, as part of her compensation package.

Denali Therapeutics Inc. Director Jay T. Flatley was granted 6,037 Restricted Stock Units and 18,111 stock options as part of his compensation, aligning his interests with shareholders.

Denali Therapeutics Inc. Director Peter S. Klein was granted 6,037 Restricted Stock Units and options to purchase 18,111 shares of common stock on June 3, 2025, as part of his compensation.

Denali Therapeutics Inc. Director Steve E. Krognes reported the acquisition of 6,037 Restricted Stock Units and 18,111 stock options as part of his compensation, aligning his interests with shareholders.

Denali Therapeutics Inc. Director David P. Schenkein has increased his beneficial ownership through the acquisition of 6,037 Restricted Stock Units and 18,111 stock options, aligning his interests further with shareholders.

Denali Therapeutics Inc. Director Nancy Thornberry was granted 6,037 Restricted Stock Units and 18,111 stock options on June 3, 2025, as part of her compensation.

Denali Therapeutics Inc. Director Marc Tessier-Lavigne has reported the acquisition of 6,037 Restricted Stock Units and 18,111 stock options, aligning his interests with shareholders.

Denali Therapeutics' Chief Medical Officer, Carole Ho, sold shares to cover tax obligations related to vested restricted stock units.